Feline Hyperthyroidism

Feline hyperthyroidism is a multisystemic endocrine disorder characterized by excessive circulating concentrations of thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), resulting from functional thyroid nodules. It is the most common endocrinopathy in middle-aged to older cats. The disease is typically caused by benign adenomatous hyperplasia (adenoma) of one or both thyroid lobes, with malignant thyroid carcinoma accounting for less than 2-5% of cases. The excessive thyroid hormone secretion leads to a hypermetabolic state affecting nearly every organ system, particularly the cardiovascular system (hypertrophic cardiomyopathy, hypertension), renal system (increased glomerular filtration rate, potential masking of chronic kidney disease), gastrointestinal system (weight loss despite polyphagia, vomiting, diarrhea), and neuromuscular system (muscle wasting, weakness). The clinical presentation can vary from subtle to severe, and the disease can be complicated by concurrent conditions, especially chronic kidney disease and cardiac disease. Early diagnosis and appropriate management are essential to prevent morbidity and mortality.

The exact etiology of feline hyperthyroidism remains incompletely understood, but it is believed to be multifactorial. The primary cause is the development of functional thyroid adenomas, which are benign monoclonal or polyclonal proliferations of thyroid follicular cells. These adenomas autonomously secrete thyroid hormones independent of normal regulatory feedback mechanisms. Several risk factors have been proposed, including chronic exposure to goitrogens in the environment or diet, such as isoflavones (e.g., in soy-based cat foods), phthalates, and certain preservatives. Additionally, chronic exposure to iodine in excess or deficiency may play a role. Genetic mutations, such as activating mutations in the thyrotropin receptor (TSHR) or G-protein alpha subunit (GNAS), have been identified in some feline thyroid adenomas, leading to constitutive activation of the cAMP pathway and uncontrolled hormone secretion. Environmental factors, including indoor living, use of cat litter, and exposure to flame retardants (polybrominated diphenyl ethers), have been associated with increased risk. However, no single causative agent has been definitively identified, and the disease likely results from an interaction of genetic predisposition and environmental triggers.

Feline hyperthyroidism is predominantly a disease of middle-aged to older cats, with a median age at diagnosis of 12-13 years. It is rare in cats younger than 8 years. There is no strong sex predilection, although some studies suggest a slight female predominance. The disease is seen worldwide but is more commonly reported in North America, Europe, and other developed regions, possibly due to increased awareness and diagnostic capabilities. Certain breeds, such as Siamese and Himalayan, may have a lower risk, while domestic shorthair cats are commonly affected. The incidence has increased over the past few decades, likely due to improved diagnostics and increased longevity of cats. Environmental factors, such as indoor confinement and the use of commercial cat foods, have been implicated as risk factors. No clear seasonal pattern has been observed.

The pathophysiology of feline hyperthyroidism involves autonomous overproduction of thyroid hormones by adenomatous thyroid tissue. The adenomas are typically benign and may involve one or both thyroid lobes. The excessive secretion of T4 and T3 leads to a hypermetabolic state, increasing the basal metabolic rate and oxygen consumption in tissues. Thyroid hormones potentiate the effects of catecholamines, leading to increased heart rate, myocardial contractility, and cardiac output. This results in cardiovascular changes, including concentric hypertrophy of the left ventricle (hypertrophic cardiomyopathy) and systemic arterial hypertension. The increased metabolic rate accelerates protein and fat catabolism, leading to weight loss despite increased appetite. Gastrointestinal motility is increased, causing vomiting and diarrhea. Hepatic enzyme induction occurs, particularly alkaline phosphatase (ALP) and alanine aminotransferase (ALT). Renal blood flow and glomerular filtration rate (GFR) are increased due to increased cardiac output and direct effects on renal vasculature, which can mask underlying chronic kidney disease (CKD). Once hyperthyroidism is treated, GFR may decrease, unmasking CKD. Thyroid hormones also affect the musculoskeletal system, causing muscle wasting and weakness. Behavioral changes, such as hyperactivity and aggression, are common due to increased catecholamine sensitivity. The negative feedback regulation of thyroid-stimulating hormone (TSH) is suppressed, but this is not sufficient to control hormone secretion from the autonomous adenomas.

Predisposing factors for feline hyperthyroidism include advanced age (typically >8 years), with the highest incidence in cats over 10 years. Genetic predisposition may play a role, as certain breeds appear to have lower risk, but no specific genetic markers have been identified. Environmental factors are significant: indoor cats are at higher risk, possibly due to increased exposure to indoor pollutants, such as flame retardants, phthalates, and other endocrine-disrupting chemicals. Dietary factors, including long-term consumption of canned cat food, particularly those containing fish, liver, or giblets, have been associated with increased risk. These foods may contain high levels of iodine or goitrogens. Chronic exposure to goitrogenic substances, such as soy isoflavones, may also contribute. Additionally, cats with a history of other endocrine diseases, such as diabetes mellitus, may be at increased risk, though this is not well established. Stress and obesity have been suggested as potential risk factors, but evidence is limited.

Clinical signs of feline hyperthyroidism are progressive and can be subtle initially. The most common presenting signs include weight loss despite a normal or increased appetite (polyphagia), which occurs in over 90% of cases. Polyuria and polydipsia are common due to increased renal blood flow and possible concurrent CKD. Gastrointestinal signs include vomiting, diarrhea, and increased frequency of bowel movements. Cardiovascular signs include tachycardia (heart rate >200 beats per minute), arrhythmias, and a systolic heart murmur, often due to hypertrophic cardiomyopathy. Respiratory signs may include tachypnea and dyspnea if congestive heart failure develops. Neuromuscular signs include muscle weakness, tremors, and a plantigrade stance (in severe cases). Behavioral changes are common, including hyperactivity, restlessness, aggression, and anxiety. Cats may also exhibit poor coat quality, with matted, greasy, or unkempt hair, and excessive grooming. In advanced cases, cats may become anorexic and lethargic, a condition known as 'apathetic hyperthyroidism,' which is more common in older cats with severe disease. Physical examination may reveal a palpable thyroid nodule (goiter) in the cervical region, though this is not always present, especially if the nodule is intrathoracic. Other findings include muscle wasting, dehydration, and a thin body condition.

Differential diagnoses for feline hyperthyroidism include: 1) Chronic kidney disease (CKD): Both conditions cause weight loss, polyuria/polydipsia, and poor coat. CKD is differentiated by elevated serum creatinine and symmetric dimethylarginine (SDMA), decreased urine specific gravity, and normal or low thyroid hormone levels. 2) Diabetes mellitus: Presents with polyphagia, polyuria/polydipsia, and weight loss. Hyperglycemia and glucosuria are diagnostic. 3) Inflammatory bowel disease (IBD) or gastrointestinal lymphoma: Causes vomiting, diarrhea, and weight loss. Abdominal ultrasound and intestinal biopsy are needed for differentiation. 4) Hepatic disease: Can cause weight loss, vomiting, and elevated liver enzymes. Liver function tests and ultrasound are helpful. 5) Chronic pancreatitis: Causes vomiting, abdominal pain, and weight loss. Feline pancreatic lipase immunoreactivity (fPLI) is elevated. 6) Neoplasia (e.g., intestinal lymphoma, pancreatic adenocarcinoma): May present with weight loss, vomiting, and anorexia. Imaging and biopsy are necessary. 7) Hypertension (primary or secondary): Can cause retinal detachment, neurological signs, and cardiac changes. Blood pressure measurement is essential. 8) Acromegaly (hypersomatotropism): Causes insulin resistance, weight gain, and respiratory signs. Insulin-like growth factor-1 (IGF-1) levels are elevated. 9) Hyperadrenocorticism (Cushing's syndrome): Causes polyuria/polydipsia, pot-bellied appearance, and skin changes. ACTH stimulation test or low-dose dexamethasone suppression test is diagnostic. 10) Chronic respiratory disease: May cause tachypnea and exercise intolerance, but thyroid hormone levels are normal.

The diagnostic algorithm for feline hyperthyroidism begins with a thorough history and physical examination, with particular attention to age, clinical signs, and palpation of the cervical region for a thyroid nodule. If hyperthyroidism is suspected, baseline laboratory tests are recommended: complete blood count (CBC), serum biochemistry profile, urinalysis, and serum total T4 (TT4) concentration. A TT4 above the reference range (typically >4.5-5.0 μg/dL or >50-60 nmol/L) confirms the diagnosis in most cases. If TT4 is within the upper half of the reference range or borderline, and clinical suspicion is high, additional testing is warranted: free T4 (fT4) by equilibrium dialysis, endogenous feline TSH (fTSH) concentration, and possibly thyroid scintigraphy. A high fT4 with suppressed fTSH is consistent with hyperthyroidism. If fT4 is normal and fTSH is suppressed, hyperthyroidism is likely. If both are normal, early or mild hyperthyroidism may be present, and repeat testing in 2-4 weeks is recommended. Thyroid scintigraphy (using technetium-99m pertechnetate) is the gold standard for confirming hyperthyroidism and determining the extent of thyroid involvement (unilateral vs. bilateral, ectopic tissue). It is particularly useful when other tests are equivocal or when planning surgical or radioactive iodine therapy. Additional diagnostic steps include assessment for concurrent diseases, such as CKD (serum creatinine, SDMA, urinalysis), hypertension (indirect blood pressure measurement), and cardiac disease (echocardiography if murmur or arrhythmia is present).

Hematology: Complete blood count may show mild erythrocytosis due to increased erythropoietin stimulation, but this is not consistent. Stress leukogram (neutrophilia, lymphopenia, eosinopenia) may be present. Serum biochemistry: Common findings include elevated liver enzymes, particularly alanine aminotransferase (ALT) and alkaline phosphatase (ALP), due to hepatic hypoxia and enzyme induction. Mild hyperbilirubinemia may occur. Blood urea nitrogen (BUN) and creatinine may be normal or slightly elevated; however, due to increased GFR, they may be lower than expected, masking underlying CKD. Electrolytes are usually normal, but hypokalemia may occur in severe cases. Hyperglycemia may be present due to stress or concurrent diabetes mellitus. Urinalysis: Urine specific gravity may be low (<1.030) if concurrent CKD is present, but can be concentrated in uncomplicated hyperthyroidism. Proteinuria may be present. Blood gas analysis: May reveal metabolic acidosis in severe cases. Specific biomarkers: Serum total T4 (TT4) is the primary diagnostic test; levels >4.5 μg/dL (or >60 nmol/L) are diagnostic. Free T4 (fT4) by equilibrium dialysis is more sensitive and specific, especially in early or mild cases. Endogenous feline TSH (fTSH) is typically suppressed (<0.03 ng/mL) in hyperthyroidism. Thyroid scintigraphy shows increased uptake of radionuclide in affected thyroid lobes. Other biomarkers: NT-proBNP may be elevated if cardiac disease is present. SDMA may be elevated if CKD is present, but can be normal in early CKD. Serum thyroglobulin autoantibodies may be present in some cats, but their role is not fully understood.

Radiography: Thoracic radiographs may reveal cardiomegaly, particularly left atrial and left ventricular enlargement, and pulmonary edema if congestive heart failure is present. Abdominal radiographs may show hepatomegaly. Ultrasonography: Abdominal ultrasound may reveal hepatomegaly, thickened stomach or intestinal walls if concurrent gastrointestinal disease, and changes consistent with CKD (small, irregular kidneys). Thyroid ultrasound can be used to evaluate the thyroid lobes, but it is less sensitive than scintigraphy for detecting functional nodules. Echocardiography: This is essential for evaluating cardiac structure and function. Common findings include concentric left ventricular hypertrophy (increased interventricular septal thickness and left ventricular free wall thickness), left atrial enlargement, and hyperdynamic systolic function. Doppler studies may reveal mitral regurgitation. Computed Tomography (CT): CT can be used to evaluate the thyroid gland and detect ectopic thyroid tissue, but it is less specific than scintigraphy. Magnetic Resonance Imaging (MRI): MRI is rarely used for thyroid evaluation but may be helpful in assessing cervical masses. Thyroid Scintigraphy: This is the imaging modality of choice for confirming hyperthyroidism and determining the extent of thyroid involvement. It involves intravenous injection of technetium-99m pertechnetate, which is taken up by functional thyroid tissue. Scintigraphy can differentiate between unilateral and bilateral disease, identify ectopic thyroid tissue (e.g., in the thorax), and guide treatment decisions (surgery vs. radioactive iodine).

Cytology: Fine-needle aspiration (FNA) of a thyroid nodule is not commonly performed because it may not distinguish between adenoma and carcinoma, and it carries a risk of hemorrhage. However, if performed, cytology may show clusters of follicular epithelial cells with variable nuclear atypia. Histopathology: Surgical biopsy or post-thyroidectomy histopathology is definitive. Adenomatous hyperplasia (adenoma) is characterized by well-demarcated, encapsulated nodules of hyperplastic follicular cells with colloid-filled follicles. Carcinoma is rare and shows capsular invasion, vascular invasion, and cellular atypia. Immunohistochemistry may be used to differentiate benign from malignant lesions, but it is not routinely performed.

Treatment of feline hyperthyroidism aims to control thyroid hormone levels and manage clinical signs. Options include medical management, surgical thyroidectomy, radioactive iodine therapy, and dietary therapy. Medical management: Antithyroid drugs, such as methimazole (Tapazole) or carbimazole, are commonly used. Methimazole is administered orally at an initial dose of 1.25-2.5 mg per cat every 12 hours, with dose adjustments based on T4 levels. The typical maintenance dose is 2.5-5 mg per cat every 12 hours. Carbimazole is a prodrug that is converted to methimazole; it is given at a dose of 1.25-2.5 mg/kg every 12 hours. Side effects include vomiting, anorexia, lethargy, and rarely hepatotoxicity or blood dyscrasias. Beta-blockers, such as propranolol (2.5-5 mg per cat every 8 hours) or atenolol (6.25-12.5 mg per cat every 12 hours), may be used to control tachycardia and hypertension. Surgical thyroidectomy: This is a curative option for unilateral disease, but it requires careful preoperative stabilization with antithyroid drugs and beta-blockers. Complications include hypoparathyroidism (if parathyroid glands are damaged) and recurrence if ectopic tissue is present. Radioactive iodine therapy (I-131): This is the treatment of choice for many cats, as it is curative in a single injection, has minimal side effects, and does not require anesthesia. It is particularly useful for bilateral disease and ectopic tissue. The dose is typically 3-5 mCi, administered subcutaneously or intravenously. Cats must be hospitalized in a licensed facility for radiation safety. Dietary therapy: A low-iodine diet (e.g., Hill's y/d) can be used to manage hyperthyroidism, but it must be fed exclusively and is not suitable for all cats. It is less effective than other treatments and may take several weeks to achieve euthyroidism. Supportive care: This includes fluid therapy for dehydration, nutritional support, and treatment of concurrent conditions such as CKD and hypertension. In emergency cases, such as thyroid storm, aggressive treatment with antithyroid drugs, beta-blockers, and supportive care is required.

The prognosis for feline hyperthyroidism is generally good with appropriate treatment. Medical management with methimazole is effective in controlling clinical signs, but it requires lifelong administration and monitoring. Surgical thyroidectomy is curative for unilateral disease, with a low recurrence rate if all functional tissue is removed. Radioactive iodine therapy is curative in over 95% of cases, with a low risk of recurrence. However, the prognosis is influenced by the presence of concurrent diseases, particularly chronic kidney disease (CKD) and cardiac disease. Cats with pre-existing CKD may experience worsening of renal function after treatment, as the increased GFR associated with hyperthyroidism is reduced. This can lead to overt renal failure, which may negatively impact survival. Cardiac disease, such as hypertrophic cardiomyopathy, may improve with treatment, but severe cardiac changes may persist. Overall, the median survival time for cats with hyperthyroidism treated with radioactive iodine is approximately 2-4 years, with many cats living longer. Negative prognostic indicators include severe muscle wasting, azotemia at diagnosis, and the presence of congestive heart failure.

Follow-up care for feline hyperthyroidism depends on the treatment modality. For cats on medical management, serum T4 levels should be rechecked 2-4 weeks after initiating therapy or after any dose adjustment. Once stable, T4 should be monitored every 3-6 months. Renal function (creatinine, SDMA, urinalysis) should be assessed at each recheck, as treatment can unmask CKD. Blood pressure should be monitored regularly, as hypertension may persist or develop. For cats treated with radioactive iodine, T4 levels should be checked at 1, 3, and 6 months post-treatment, then every 6-12 months. Hypothyroidism may develop in some cats, requiring thyroid hormone supplementation. For cats treated surgically, T4 should be checked 1-2 months post-operatively, then every 6-12 months. All cats should have a complete physical examination, including body weight, body condition score, and cardiac auscultation, at each visit. If cardiac disease is present, echocardiography should be repeated every 6-12 months. Owners should be educated on the signs of hyperthyroidism recurrence and the importance of regular monitoring.

Pearls: 1) Always measure total T4 in any cat over 8 years with weight loss, polyphagia, or vomiting. 2) A normal total T4 does not rule out hyperthyroidism; if suspicion is high, measure free T4 and TSH. 3) Palpate the thyroid gland gently; a palpable nodule is a strong indicator. 4) Treat hypertension and cardiac disease concurrently. 5) When starting methimazole, consider a 2-week trial at a low dose to assess tolerance. 6) Radioactive iodine is the gold standard for definitive treatment. Pitfalls: 1) Do not rely solely on total T4; it can be normal in early or mild disease. 2) Avoid using methimazole in cats with severe hepatic disease. 3) Do not overlook concurrent CKD; treat hyperthyroidism cautiously to avoid worsening renal function. 4) Do not use beta-blockers as sole therapy; they do not reduce thyroid hormone levels. 5) Do not perform surgery without preoperative stabilization. 6) Do not forget to monitor for hypothyroidism after radioactive iodine or surgery.

Antithyroid drugs: Methimazole (Tapazole) - Initial dose: 1.25-2.5 mg per cat PO q12h. Maintenance: 2.5-5 mg per cat PO q12h. Maximum dose: 10 mg per cat q12h. Carbimazole (Vidalta) - Initial dose: 1.25-2.5 mg/kg PO q12h. Maintenance: 1.25-2.5 mg/kg PO q12h. Beta-blockers: Propranolol - 2.5-5 mg per cat PO q8h. Atenolol - 6.25-12.5 mg per cat PO q12h. For emergency management of thyroid storm: Methimazole 2.5 mg per cat PO q12h, propranolol 2.5-5 mg per cat PO q8h, and supportive care with IV fluids. Dosage adjustments: In cats with renal impairment, methimazole may require lower doses. Contraindications: Methimazole is contraindicated in cats with severe hepatic disease or blood dyscrasias. Drug interactions: Methimazole may increase the risk of bleeding when used with anticoagulants. Beta-blockers should be used with caution in cats with asthma or heart failure. Always refer to Plumb's Veterinary Drug Handbook for detailed information.

Key studies and consensus guidelines: 1) The 2016 ACVIM consensus statement on the diagnosis and treatment of feline hyperthyroidism provides evidence-based recommendations. 2) A study by Peterson et al. (2016) demonstrated that radioactive iodine therapy is safe and effective, with a cure rate of over 95%. 3) A study by Wakeling et al. (2008) identified risk factors for hyperthyroidism, including indoor living and canned food consumption. 4) A study by Williams et al. (2010) showed that methimazole is effective in controlling hyperthyroidism but requires careful monitoring. 5) A study by Syme et al. (2001) found that hyperthyroid cats with pre-existing CKD have a worse prognosis. 6) A study by Norsworthy et al. (2013) evaluated the use of a low-iodine diet and found it effective in managing hyperthyroidism. 7) A meta-analysis by Scott-Moncrieff (2015) summarized the efficacy of different treatment modalities. 8) The International Renal Interest Society (IRIS) guidelines recommend monitoring renal function in hyperthyroid cats. 9) The European Advisory Board on Cat Diseases (ABCD) has published guidelines on feline hyperthyroidism. These studies and guidelines support the current diagnostic and therapeutic approaches.